Mark Sullivan Sells 13,008 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Definium Therapeutics Trading Up 0.4%

Shares of NASDAQ:DFTX opened at $44.95 on Friday. The company’s 50-day moving average price is $24.59 and its two-hundred day moving average price is $19.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. Definium Therapeutics, Inc. has a one year low of $6.40 and a one year high of $47.01. The stock has a market capitalization of $4.48 billion, a PE ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, equities analysts forecast that Definium Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP grew its stake in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after buying an additional 475,000 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in Definium Therapeutics during the third quarter worth approximately $4,337,000. Rosalind Advisors Inc. boosted its holdings in shares of Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after acquiring an additional 239,965 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after purchasing an additional 198,878 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Wall Street Analysts Forecast Growth

DFTX has been the subject of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Canaccord Genuity Group set a $60.00 price objective on Definium Therapeutics in a report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, JonesTrading upped their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $47.08.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.